Male Hypogonadism Commonly Missed Diagnoses: A Clinical Guide

What the guidelines actually require

The Endocrine Society's 2018 clinical practice guideline recommends diagnosing hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone [1]. The initial test is a fasting morning total testosterone measured with an accurate and reliable assay, and the diagnosis is confirmed by repeating that measurement [1]. The AUA guideline, published in 2018 and validity-confirmed in 2024, uses a total testosterone below 300 ng/dL as a reasonable cutoff and requires two measurements on separate occasions, both taken early in the morning; a single low value, or symptoms alone, are not enough [2].

Where the numbers come from matters. A harmonization study of 9,054 men in four cohort studies, cross-calibrated to a CDC reference method, put the total testosterone range in healthy non-obese men aged 19 to 39 at 264 to 916 ng/dL (2.5th to 97.5th percentile), with a median of 531 ng/dL and a 5th percentile of 303 ng/dL [3]. That leaves two anchors in common use: about 264 ng/dL as the harmonized lower limit of the young healthy range, and 300 ng/dL as the AUA diagnostic cutoff [3][2].

The Endocrine Society does not recommend screening the general population [1]. A diagnosis requires compatible symptoms and signs together with consistently low testosterone [1].

How common low values are

The Hypogonadism in Males study measured total testosterone in 2,162 men aged 45 and older visiting US primary care practices and found 38.7% below 300 ng/dL; 80 of the 836 men with low values were receiving testosterone [6]. Samples in that study were drawn between 8 a.m. and noon [6].

Missed diagnosis 1: normal aging

Testosterone does fall with age. In the Baltimore Longitudinal Study of Aging, which measured testosterone in stored samples from 890 men, total testosterone declined by an average of 0.124 nmol/L per year, and the share of men with values in the hypogonadal range rose to about 20% over age 60, 30% over 70 and 50% over 80 [8].

The Endocrine Society suggests against routinely prescribing testosterone to all men aged 65 or older who have low testosterone; for men with symptoms and consistently low morning levels it suggests an individualized discussion of risks and benefits [1]. The American College of Physicians' 2020 guideline, which addresses age-related low testosterone, suggests discussing testosterone only with men who have sexual dysfunction and want better sexual function, reevaluating within 12 months and stopping if sexual function does not improve, and not starting it to improve energy, vitality, physical function or cognition [9].

The regulatory line sits in a different place. FDA states that its approved testosterone products are for men who lack or have low testosterone together with an associated medical condition such as testicular failure or a hypothalamus or pituitary problem, and that no approved product is for men with low testosterone who have no such condition [5]. The Testim and Depo-Testosterone labels still carry a Limitation of Use saying safety and efficacy in age-related hypogonadism have not been established [4][10]. In June 2026 FDA asked manufacturers to remove that limitation and to revise prostate cancer and benign prostatic hyperplasia safety information; whether each label has been updated yet is not confirmed [5].

Missed diagnosis 2: depression

Low mood, poor concentration, low libido and fatigue appear in both pictures. A 2019 meta-analysis in JAMA Psychiatry pooled 27 randomized placebo-controlled trials including 1,890 men and found testosterone treatment reduced depressive symptom scores by a small amount (Hedges g 0.21, 95% CI 0.10 to 0.32) [11]. An earlier meta-analysis of 7 placebo-controlled trials in 364 depressed patients found a significant effect on Hamilton Depression Rating Scale response (z=4.04) [12].

A small average shift on a depression scale is not the same as depression being hypogonadism. A mood score cannot diagnose hypogonadism; that still requires the confirmed low morning testosterone pattern described above [1][2].

Missed diagnosis 3: obstructive sleep apnea

Sleep apnea and hypogonadism can both come with daytime fatigue, poor concentration and low libido. A 2014 review in the Asian Journal of Andrology concluded that obstructive sleep apnea appears to have no direct effect on testosterone after adjusting for age and obesity, and that treating moderate-to-severe apnea with CPAP does not reliably raise testosterone in most studies, whereas weight loss does, in proportion to the amount of weight lost [13].

Testosterone peaks during sleep and reaches its lowest point in the late afternoon [13]. The guidelines specify morning sampling [1][2].

One overlap does run the other way. Untreated severe obstructive sleep apnea is on the Endocrine Society's list of conditions in which it recommends against starting testosterone [1].

Missed diagnosis 4: type 2 diabetes and obesity

In the HIM study, men with diabetes had 2.09 times the odds of hypogonadism and men with obesity 2.38 times the odds, compared with men without those conditions [6]. Despite that association, the Endocrine Society recommends against using testosterone to improve glycemic control in type 2 diabetes [1].

Missed diagnosis 5: anemia

Anemia is a competing explanation for fatigue, but low testosterone and anemia are also associated. A 2006 study in the Archives of Internal Medicine measured testosterone and hemoglobin in 905 adults aged 65 and older: men in the lowest quartile of total testosterone were more likely to be anemic at baseline (14 of 99 versus 3 of 100; odds ratio 5.4, 95% CI 1.4 to 21.8) [14]. Among non-anemic men and women, low total testosterone was associated with a relative risk of 2.1 for developing anemia over 3 years (95% CI 1.1 to 4.1) [14]. The Depo-Testosterone label describes androgens as stimulating red blood cell production by enhancing production of erythropoietic stimulation factor [10].

The workup that separates them

The steps are specified. Fasting morning total testosterone first, repeated to confirm [1]. If total testosterone is near the lower limit of normal, or a condition alters sex hormone-binding globulin, free testosterone by equilibrium dialysis or an accurate formula [1]. In men with confirmed deficiency, further testing to find the cause, including LH and FSH to separate primary from secondary hypogonadism [1].

The two patterns look different. Primary hypogonadism is testicular failure, from cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals, and these men usually have low testosterone with FSH and LH above the normal range [4]. Hypogonadotropic (secondary) hypogonadism is gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation, with low testosterone and FSH and LH in the normal or low range [4].

If the diagnosis holds: what is approved

Testosterone products are labeled for replacement therapy in men with primary or hypogonadotropic hypogonadism [4][10]. The Depo-Testosterone label gives a replacement range of 50 to 400 mg every two to four weeks by intramuscular injection [10]. The Testim label starts at 50 mg of gel daily and increases to 100 mg if the morning pre-dose testosterone is below the normal range, states that it is not substitutable with other topical testosterone products, and carries a boxed warning about secondary exposure of children to application sites [4]. Human chorionic gonadotropin is FDA-approved for selected cases of hypogonadotropic hypogonadism due to pituitary deficiency in males [15].

Two drugs often mentioned for low testosterone are not approved for it. Clomiphene citrate is approved only for ovulatory dysfunction in women, so male use is off-label [16]; in one small single-arm study of 36 men given 25 mg daily, mean testosterone rose from 247.6 to 610.0 ng/dL by the first follow-up at 4 to 6 weeks, with no side effects reported and no placebo group [17]. Anastrozole is approved for breast cancer in postmenopausal women, not for male hypogonadism [18].

Fertility changes the choice. Exogenous testosterone suppresses spermatogenesis, the Endocrine Society recommends against starting it in men planning fertility in the near term, and the AUA statement is that it should not be prescribed to men currently trying to conceive [1][2].

Monitoring and cardiovascular safety

The Endocrine Society recommends aiming for mid-normal-range testosterone with any approved formulation and, during the first year, evaluating symptoms, adverse effects and compliance, measuring serum testosterone and hematocrit, and evaluating prostate cancer risk [1]. The Testim label says hematocrit should be checked before starting treatment and that it would be appropriate to re-evaluate it 3 to 6 months after starting and then annually; if hematocrit becomes elevated, the label says to stop therapy until hematocrit decreases to an acceptable concentration [4]. The guideline recommends against starting testosterone in men with a PSA above 4 ng/mL, or above 3 ng/mL in men at increased prostate cancer risk without further urological evaluation [1].

TRAVERSE randomized 5,246 men aged 45 to 80 who had symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL and existing or high risk of cardiovascular disease to 1.62% testosterone gel or placebo gel [7]. A first major cardiovascular event occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), with mean treatment 21.7 months and mean follow-up 33.0 months [7]. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often with testosterone [7]; the Testim label lists atrial fibrillation at 3.5% versus 2.4% and acute kidney injury at 2.3% versus 1.5% [4].

The boxed warnings have changed. FDA's class-wide labeling action of 2/28/2025 removed language about increased cardiovascular risk from the Boxed Warning of all testosterone products and required a blood pressure warning where one was missing [19]. Other boxed warnings remain product-specific: Aveed carries warnings for serious pulmonary oil microembolism reactions and anaphylaxis, while Testim carries a boxed warning about secondary exposure to testosterone gel in children [20][4].